Research at National Jewish Health and other institutions has shown that the biologic dupilumab improves signs and symptoms of moderate-to-severe atopic dermatitis (eczema) in young children whether or not they have another inflammatory condition, such as asthma, allergic rhinitis or food allergies.
4 medtech companies to watch this week in earnings
Listen to the article 4 min This audio is auto-generated. Please let us know if you have feedback. Investor concerns about weaker order growth in
October 30, 2023